Trial Summary:

A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

Supported By:

UK Medical Research Council Clinical Trials Unit (MRC CTU)

Eligibility:

Patients who have had an RCC resected are eligible for randomisation into SORCE providing they are at intermediate or high risk of relapse (Leibovich intermediate score 3-5, high score 6-11) and satisfy the inclusion/exclusion criteria.

Registration ID:

ACTRN12609000048280

Participation:

International

Australian Lead Group:

ANZUP

Status:

Completed

Activation Date:

6^th May 2009

Chairs:

Prof Ian Davis

Contact:

sorce.study@sydney.edu.au